Evidence Snapshot
Regulatory Context
Not FDA-approved; a July 2026 FDA advisory committee voted to recommend Semax for 503A compounding-list inclusion, but that non-binding vote does not establish approval, safety, or effectiveness.
Research Takeaway
Semax is a synthetic seven-amino-acid peptide commonly represented as Met-Glu-His-Phe-Pro-Gly-Pro, derived from the ACTH(4-7) sequence with a Pro-Gly-Pro extension. Semax must not be merged with 4-10 Semax, N-acetyl Semax amidate, N-acetyl Semax, or other amidated, acetylated, or salt variants.
See all 15 evidence claims →Quick Summary
Semax is a synthetic peptide-based compound often discussed for focus, cognition, and neuroprotective mechanisms. It has more regional history of use than many gray-market peptides, but U.S.-style FDA-approved indications for common nootropic claims are lacking. This page summarizes Semax's regulatory status, small/limited human evidence, preclinical findings, and anecdotal nootropic reports.
Mechanism & Research Overview
Semax is a synthetic heptapeptide derived from the ACTH(4-7) sequence with a C-terminal Pro-Gly-Pro extension. Its proposed neurobiological actions have been studied mainly in rodents and cell systems rather than established through human mechanistic trials. In rat basal forebrain, intranasal Semax increased brain-derived neurotrophic factor (BDNF) protein within hours, and radiolabeled Semax showed specific, reversible binding to membrane preparations. Separate rat studies reported changes in BDNF, NGF, TrkB, and other gene-expression programs associated with neural plasticity and responses to cerebral ischemia. These findings support a neurotrophic-signaling hypothesis, but the molecular target responsible for these effects has not been established.
Read more about the mechanism
Experimental ischemia studies indicate broader transcriptional effects. In rat focal cerebral ischemia, Semax altered expression of genes related to vascular function, immune responses, neurotrophins, and inflammatory signaling. Proteomic work has also reported changes in brain protein-expression patterns after experimental ischemia. These results suggest that Semax may influence multiple stress-response pathways rather than act through one confirmed receptor. Translation from these models to clinical outcomes remains uncertain.
Neurochemical experiments also suggest effects on monoaminergic systems. Rodent work has reported increased serotonin metabolite levels and potentiation of amphetamine-associated dopamine release, while pain-model studies cited by FDA suggest serotonergic signaling may contribute to some experimental effects. FDA additionally highlighted animal findings suggesting changes in coagulation and fibrinolysis, including reduced platelet aggregation in some models. Those observations are relevant to safety interpretation because they raise a theoretical bleeding concern, but they do not establish a clinical antithrombotic effect in humans.
Small human neuroimaging studies provide evidence that Semax can acutely alter functional brain-network measures. A 2020 study of 52 healthy participants comparing Semax, Selank, and placebo reported treatment-related differences in resting-state connectivity involving the right amygdala and temporal regions. This is mechanistic evidence rather than evidence of clinical benefit. Overall, the mechanistic literature is biologically interesting but dominated by preclinical studies and small exploratory human experiments.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Semax is a synthetic seven-amino-acid peptide commonly represented as Met-Glu-His-Phe-Pro-Gly-Pro, derived from the ACTH(4-7) sequence with a Pro-Gly-Pro extension. Semax must not be merged with 4-10 Semax, N-acetyl Semax amidate, N-acetyl Semax, or other amidated, acetylated, or salt variants.
Sources: FDA Evaluation of Semax-Related Bulk Drug Substances
Supported
FDA's 2026 Semax evaluation identified inconsistent naming, inadequate characterization, missing information on impurities, aggregates, endotoxin and bioburden, limited human safety data, no identified human pharmacokinetic data, and potential immunogenicity for intranasal and injectable use. FDA staff concluded that evidence was insufficient for cerebral ischemia, migraine, and trigeminal neuralgia and recommended against 503A-list inclusion.
Sources: FDA Evaluation of Semax-Related Bulk Drug Substances
Supported
On July 24, 2026, the FDA Pharmacy Compounding Advisory Committee reportedly voted to recommend possible 503A-list inclusion of Semax. The recommendation was advisory and nonbinding. It did not make Semax FDA approved, establish an indication, prove safety or effectiveness, or create an approved dosing regimen. Final FDA action was not identified as of 2026-07-26.
Sources: FDA advisers recommend relaxing U.S. rules on compounding peptides
Supported
Semax human literature is limited, geographically concentrated, and often difficult to evaluate because of incomplete reporting, unclear formulation identity, small samples, and limited independent replication. No adequate evidence establishes that Semax improves cognition in healthy adults, treats stroke or prevents neurologic disability, treats migraine or trigeminal neuralgia, treats anxiety, depression, ADHD, traumatic brain injury, or neurodegenerative disease, or improves athletic performance or recovery.
Sources: FDA Evaluation of Semax-Related Bulk Drug Substances
Supported
Semax safety is inadequately characterized. Important uncertainties include immunogenicity, aggregation and peptide impurities, inconsistent identity and salt form, sterility/endotoxin/microbial-quality concerns for injectable or nasal products, unknown subcutaneous safety, limited long-term neurologic, cardiovascular, psychiatric, reproductive, hepatic, and renal safety data, and a possible antithrombotic effect with theoretical bleeding risk identified by FDA.
Sources: FDA Evaluation of Semax-Related Bulk Drug Substances
Supported
Semax is not a component of an FDA-approved drug and has no FDA-approved indication.
Sources: FDA Significant Safety Risks for Certain Compounded Bulk Substances
Supported
No FDA-approved Semax dosing regimen exists. Russian study regimens and compounding nominations must not be converted into consumer instructions.
Sources: FDA Evaluation of Semax-Related Bulk Drug Substances; FDA Significant Safety Risks for Certain Compounded Bulk Substances
Supported
In rodent studies, Semax has increased BDNF-related signaling and altered expression of neurotrophin, vascular, immune, and inflammatory-response genes, including after experimental cerebral ischemia; these findings are preclinical and do not establish clinical benefit.
Sources: Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain; The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis; Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia
Supported
Small human neuroimaging studies have reported acute Semax-associated changes in resting-state brain connectivity, but these experiments measured imaging endpoints rather than clinical efficacy.
Supported
Published Russian clinical studies have examined Semax in ischemic stroke and optic-nerve disorders, but the literature is small, geographically concentrated, and often incompletely reported by current trial standards.
Sources: Effectiveness of Semax in acute period of hemispheric ischemic stroke; The efficacy of Semax in the treatment of patients at different stages of ischemic stroke; Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease; Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone
Supported
A small open-label study in motor neuron disease found no effect of Semax on chronic partial denervation or clinical functional measures, although a quality-of-life signal was reported.
Supported
FDA's 2026 review identified insufficient clinical information to characterize Semax safety, no identified human pharmacokinetic studies, no safety data for the proposed subcutaneous route, and potential immunogenicity and aggregation concerns for compounded products.
Sources: FDA Evaluation of Semax-Related Bulk Drug Substances
Supported
FDA noted animal findings of reduced platelet aggregation and increased fibrinolytic activity after Semax exposure and identified a theoretical bleeding concern, particularly when combined with other factors that increase bleeding risk; corresponding human clinical risk has not been established.
Sources: FDA Evaluation of Semax-Related Bulk Drug Substances
Supported
On July 24, 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend Semax-related bulk drug substances for possible inclusion on the 503A Bulks List; the committee's advice is non-binding and does not make Semax FDA-approved.
Sources: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — Meeting Materials; FDA advisers recommend relaxing U.S. rules on compounding peptides
Supported
FDA's 2026 review found that published and nomination materials did not adequately resolve whether some Semax reports involved free base or acetate, and FDA identified missing characterization information on impurities, aggregates, endotoxins, microbial bioburden, and proposed nasal-device performance.
Sources: FDA Evaluation of Semax-Related Bulk Drug Substances
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Not FDA-approved in the U.S. for cognition, anxiety, depression, focus, or neuroenhancement claims.Safety Consideration
Human evidence varies by compound, region, language, and study quality.Safety Consideration
Anxiety, irritability, overstimulation, sedation, headache, nasal irritation, or sleep changes may be reported anecdotally.Safety Consideration
Psychiatric history, stimulant use, sedatives, antidepressants, and neurologic conditions require clinician caution.Safety Consideration
Product identity, nasal formulation quality, sterility, and dose consistency may vary outside regulated supply.
Research Areas Being Studied
Research areas discussed on this page reflect the Cognitive / Neuro category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Functional connectomics of Selank/Semax (2020): Assessed effects of Selank and Semax on brain functional connectivity.
- The efficacy of Semax in the treatment of patients at different stages of ischemic stroke (2018):
- The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with Semax (2007):
- Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone (2001):
- Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease (2000):
- Effectiveness of Semax in acute period of hemispheric ischemic stroke (1997):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Functional connectomics of Selank/Semax | 2020 | Human neuroimaging study | Resting-state functional connectivity — Assessed effects of Selank and Semax on brain functional connectivity. | Human data; interpret within the studied population, dose, duration, and endpoints. Review full paper for adverse events and exclusions. | |
| The efficacy of Semax in the treatment of patients at different stages of ischemic stroke | 2018 | Ischemic stroke patients at different disease stages (human) | A Russian clinical report examined Semax at different stages of ischemic stroke and described BDNF-related clinical observations. Study-design limitations (small sample, older reporting standards) must remain visible; this does not establish stroke treatment efficacy. | ||
| The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with Semax | 2007 | Motor neuron disease patients (human, open-label) | A small open-label study in motor neuron disease found no effect of Semax on chronic partial denervation or clinical functional measures, although a quality-of-life signal was reported. An important negative/neutral functional-evidence data point. | ||
| Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone | 2001 | Glaucomatous optic neuropathy patients (human) | A comparative Russian study examined Semax in glaucomatous optic neuropathy in patients with normalized ophthalmic tone. Small sample size and older reporting standards limit generalizability. | ||
| Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease | 2000 | Optic nerve disease patients (human) | A controlled comparative Russian study evaluated Semax in optic nerve disease. Small sample size and older reporting standards limit generalizability. | ||
| Effectiveness of Semax in acute period of hemispheric ischemic stroke | 1997 | Acute hemispheric ischemic stroke patients (human) | An older Russian human study in the acute period of hemispheric ischemic stroke reported effects associated with Semax. The report is small, geographically concentrated, and incompletely reported by modern trial-design standards; FDA's 2026 review found human evidence insufficient for cerebral ischemia. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis | 2014 | Animal/model study | Brain ischemia/neuroprotection pathways — Shows Semax effects on genes related to vascular and immune response pathways. | Preclinical only; animal/cell findings do not establish human safety or efficacy. | |
| Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia | 2010 | Rat focal cerebral ischemia model (preclinical) | In rat focal cerebral ischemia, Semax and its Pro-Gly-Pro fragment activated transcription of neurotrophin and neurotrophin-receptor genes, a preclinical finding relevant to the neurotrophic-signaling hypothesis and not a clinical outcome. | ||
| Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain | 2006 | Rat basal forebrain (preclinical) | In rat basal forebrain, intranasal Semax increased BDNF protein within hours, and radiolabeled Semax showed specific, reversible binding to membrane preparations, supporting a neurotrophic-signaling hypothesis without establishing the responsible molecular target. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| FDA advisers recommend relaxing U.S. rules on compounding peptides | 2026 | On July 24, 2026, the FDA Pharmacy Compounding Advisory Committee reportedly voted to recommend possible 503A-list inclusion of Semax. The recommendation was advisory and nonbinding and did not make Semax FDA approved, establish an indication, prove safety or effectiveness, or create an approved dosing regimen. | |||
| FDA Evaluation of Semax-Related Bulk Drug Substances | 2026 | FDA's 2026 Semax evaluation identified inconsistent naming, inadequate characterization, missing information on impurities, aggregates, endotoxin and bioburden, limited human safety data, no identified human pharmacokinetic data, and potential immunogenicity for intranasal and injectable use. FDA staff concluded evidence was insufficient for cerebral ischemia, migraine, and trigeminal neuralgia and recommended against 503A-list inclusion. FDA also identified a possible antithrombotic effect and theoretical bleeding risk. | |||
| FDA Significant Safety Risks for Certain Compounded Bulk Substances | 2026 | FDA separately identifies Selank acetate among compounded substances that may present significant safety risks because of potential immunogenicity, aggregation, peptide-related impurities, and limited safety information. | |||
| July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — Meeting Materials | 2026 | Official meeting materials confirming formal PCAC consideration of Semax free base and Semax acetate for possible 503A Bulks List inclusion on July 23-24, 2026. Committee advice recorded here is non-binding and is not a final FDA action. | No source link available |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Semax review | 2025 | Review | Neuroprotective/nootropic research — Summarizes Semax pharmacology and possible neuroprotective applications. | Secondary source; useful for context but not a substitute for primary study review. | |
| Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome | 2006 | Review | Dopamine/BDNF/nootropic effects — Discusses Semax effects on memory, attention, dopamine, and BDNF. | Secondary source; useful for context but not a substitute for primary study review. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Nothing on this page is a mental-health treatment claim or a suggestion to use Semax for anxiety, depression, ADHD, stroke, or other cognitive disorders outside licensed clinician care.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-12.
Follow research updates for Semax
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.